UCB S.A.
Company Snapshot
Founded: 1928
Entity Type: Public
Employees: 10,117
Region: U.S.
Revenue: $8,755.2 Millions
Revenue Year: 2025
Headquarter: Brussels, Belgium
Key Geographics: U.S., Europe, Germany, Japan, Spain, France, Italy, U.K., Ireland, China, Belgium, Other Countries
Corporate Address: Allée de la Recherche, 60 1070 Brussels, Belgium Tel. +32-2-559-9999 www.ucb.com
Company Overview
UCB S.A., a multinational biopharma company, aims to enhance the quality of life for those suffering from serious neurological and immunological disorders. It has a presence across 40 countries worldwide. It has invested in biopharmaceutical research and spearheaded innovations. It has three business operating segments: neurology, immunology, and established brands.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Company's Business Segments
- Immunology : CIMZIA, BIMZELX, EVENITY
- Neurology : BRIVIACT, KEPPRA, FINTEPLA, VIMPAT, RYSTIGGO, NAYZILAM, ZILBRYSQ
- Established Brands : Atarax, Nootropil
Applications/End User Industries
- Biotechnology
- Life Sciences
- Healthcare
- Pharmaceuticals
- Immunology
- Neurology